MHRA extends the license of two cystic fibrosis drugs for children aged two to five years old

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 November 2023) extended the licence of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old.

Bioelectronic ‘living pharmacy’ implant could transform diabetes and obesity care

A Carnegie Mellon University-led team of researchers has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H).

October 3, 2024

Sammy Basso, progeria advocate, has died at 28

We generally don’t think of rare-disease advocacy as funny. But of the many qualities apparent to anyone who met Sammy Basso, a biologist and spokesperson

October 6, 2024

Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. – Biotech Investments

Spexis AG / Key word(s): Miscellaneous 30-Apr-2024 / 20:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely

May 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.